About: High Frequency of Antiphospholipid Antibodies in Critically‐ill COVID‐19 Patients: a Link with Hypercoagulability?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: High Frequency of Antiphospholipid Antibodies in Critically‐ill COVID‐19 Patients: a Link with Hypercoagulability? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	High Frequency of Antiphospholipid Antibodies in Critically‐ill COVID‐19 Patients: a Link with Hypercoagulability?
Creator	Combes, Alain Amoura, ; Frere, Corinne Hekimian, Guillaume Martin-Toutain, Isabelle Mathian, Alexis Miyara, Makoto Pineton De Chambrun, Marc
Source	Medline; PMC
abstract	Coronavirus disease 2019 (COVID‐19) is associated with both severe systemic inflammation and a prothrombotic state, as reflected by significant increases in fibrinogen and D‐dimers levels that have been associated with poor prognosis and high rates of severe pulmonary embolism. A recent report suggested a role for antiphospholipid antibodies (aPLA) in the thrombotic manifestations associated with severe COVID‐19. As we also recently noticed unexplained lengthening of activated partial thromboplastin time (aPTT) in some critically ill COVID‐19 patients, we explored our patients for aPLA positivity.
has issue date	2020-06-12(xsd:dateTime)
bibo:doi	10.1111/joim.13126
bibo:pmid	32529774
has license	no-cc
sha1sum (hex)	66b6af90675301885544e656c2d0172740531efc
schema:url	https://doi.org/10.1111/joim.13126
resource representing a document's title	High Frequency of Antiphospholipid Antibodies in Critically‐ill COVID‐19 Patients: a Link with Hypercoagulability?
has PubMed Central identifier	PMC7307032
has PubMed identifier	32529774
schema:publication	J Intern Med
resource representing a document's body	covid:66b6af90675301885544e656c2d0172740531efc#body_text
is schema:about of	named entity 'extracorporeal membrane oxygenation' named entity 'refractory' named entity 'COVID' named entity 'ARDS' named entity 'aPPT' named entity 'Hypercoagulability' named entity 'heparin' named entity 'High Frequency' named entity 'LINK' named entity 'Antiphospholipid Antibodies' named entity 'COVID-19' named entity 'Patients' named entity 'High Frequency' named entity 'Link' named entity 'ILL' named entity 'PATIENTS' named entity 'Hypercoagulability' named entity 'Antibodies' named entity 'COVID-19' named entity 'ANTIPHOSPHOLIPID ANTIBODIES' named entity 'HYPERCOAGULABILITY' named entity 'HIGH FREQUENCY' named entity 'COVID-19'
is part of of	covid:66b6af90675301885544e656c2d0172740531efc#body_text High Frequency of Antiphospholipid Antibodies in Critically‐ill COVID‐19 Patients: a Link with Hypercoagulability? Coronavirus disease 2019 (COVID‐19) is associated with both severe systemic inflammation and a prothrombotic state, as reflected by significant increases in fibrinogen and D‐dimers levels that have been associated with poor prognosis and high rates of severe pulmonary embolism. A recent report suggested a role for antiphospholipid antibodies (aPLA) in the thrombotic manifestations associated with severe COVID‐19. As we also recently noticed unexplained lengthening of activated partial thromboplastin time (aPTT) in some critically ill COVID‐19 patients, we explored our patients for aPLA positivity.

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software